Brought to you by 
Panax to acquire Sangen Pharmaceuticals
13 Jul 1999
Executive Summary
To expand its focus beyond discovery to development, Panax Pharmaceutical (drugs from traditional medicinal plants) signed an agreement in principle to merge Sangen Pharmaceutical, acquiring the private biotech in a stock swap.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Panax to acquire Sangen Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice